Cas no 115761-61-0 (1-Biphenyl-3-yl-piperazine)
1-Biphenyl-3-yl-piperazine Chemical and Physical Properties
Names and Identifiers
-
- 1-Biphenyl-3-yl-piperazine
- 1-(3-Biphenylyl)piperazine
- 1-(Biphenyl-3-yl)piperazine
- Piperazine,1-[1,1'-biphenyl]-3-yl-
- 1-(3-phenylphenyl)piperazine
- 1-(3-BIPHENYLYL)-PIPERAZINE >98%
- MFCD06201887
- EN300-1700295
- PS-3222
- BDBM50395190
- SCHEMBL1914606
- FT-0642819
- AKOS015914205
- CHEMBL2164331
- MHBONQZDOYFHIB-UHFFFAOYSA-N
- CS-0199930
- 3-[1-piperazinyl]biphenyl
- 1-biphenyl-3-ylpiperazine
- 115761-61-0
- 1-biphenyl-3-ylpiperazin
- A803481
- 1-([1,1'-biphenyl]-3-yl)piperazine
- 1-{[1,1'-biphenyl]-3-yl}piperazine
- 1-(3-Biphenylyl)-piperazine
- Piperazine, 1-[1,1'-biphenyl]-3-yl-
- DTXSID30373491
- DB-017186
- DTXCID70324523
-
- MDL： MFCD06201887
- Inchi： 1S/C16H18N2/c1-2-5-14(6-3-1)15-7-4-8-16(13-15)18-11-9-17-10-12-18/h1-8,13,17H,9-12H2
- InChI Key： MHBONQZDOYFHIB-UHFFFAOYSA-N
- SMILES： N1(C2C=CC=C(C3C=CC=CC=3)C=2)CCNCC1
Computed Properties
- Exact Mass: 238.14700
- Monoisotopic Mass: 238.147
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 1
- Hydrogen Bond Acceptor Count: 2
- Heavy Atom Count: 18
- Rotatable Bond Count: 2
- Complexity: 242
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 2.7
- Topological Polar Surface Area: 15.3A^2
Experimental Properties
- Color/Form: Pale-yellow to Yellow-brown Solid
- Density: 1.068
- Melting Point: 69 °C
- Boiling Point: 430.8 °C at 760 mmHg
- Flash Point: 198.4 °C
- Refractive Index: 1.581
- PSA: 15.27000
- LogP: 3.15700
1-Biphenyl-3-yl-piperazine Security Information
- Signal Word：Warning
- Hazard Statement： H302;H315;H319;H335
- Warning Statement： P261;P305+P351+P338
-
Hazardous Material Identification：
- Storage Condition：2-8 °C
1-Biphenyl-3-yl-piperazine Customs Data
- HS CODE：2933599090
- Customs Data：
China Customs Code:
2933599090Overview:
2933599090. Other compounds with pyrimidine ring in structure(Including other compounds with piperazine ring on the structure. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date
Summary:
2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
1-Biphenyl-3-yl-piperazine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| Chemenu | CM169703-5g |
1-(Biphenyl-3-yl)piperazine |
115761-61-0 | 95% | 5g |
$419 | 2021-08-05 | |
| TRC | B522628-50mg |
1-Biphenyl-3-yl-piperazine |
115761-61-0 | 50mg |
$ 50.00 | 2022-06-07 | ||
| TRC | B522628-100mg |
1-Biphenyl-3-yl-piperazine |
115761-61-0 | 100mg |
$ 65.00 | 2022-06-07 | ||
| TRC | B522628-500mg |
1-Biphenyl-3-yl-piperazine |
115761-61-0 | 500mg |
$ 210.00 | 2022-06-07 | ||
| Alichem | A139001776-5g |
1-Biphenyl-3-yl-piperazine |
115761-61-0 | 95% | 5g |
$489.72 | 2023-09-04 | |
| Fluorochem | 022120-1g |
1-(3-Biphenylyl)piperazine |
115761-61-0 | 98% | 1g |
￡109.00 | 2022-02-28 | |
| Fluorochem | 022120-2g |
1-(3-Biphenylyl)piperazine |
115761-61-0 | 98% | 2g |
￡177.00 | 2022-02-28 | |
| Fluorochem | 022120-5g |
1-(3-Biphenylyl)piperazine |
115761-61-0 | 98% | 5g |
￡367.00 | 2022-02-28 | |
| Apollo Scientific | OR0864-1g |
1-(Biphenyl-3-yl)piperazine |
115761-61-0 | 98% | 1g |
￡155.00 | 2025-02-19 | |
| Chemenu | CM169703-1g |
1-(Biphenyl-3-yl)piperazine |
115761-61-0 | 95%+ | 1g |
$144 | 2023-11-24 |
1-Biphenyl-3-yl-piperazine Related Literature
-
Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
-
Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
-
Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
-
Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
-
Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
Additional information on 1-Biphenyl-3-yl-piperazine
Recent Advances in the Study of 1-Biphenyl-3-yl-piperazine (CAS: 115761-61-0) in Chemical Biology and Pharmaceutical Research
1-Biphenyl-3-yl-piperazine (CAS: 115761-61-0) is a compound of significant interest in the field of chemical biology and pharmaceutical research. Recent studies have highlighted its potential as a versatile scaffold in drug discovery, particularly in the development of therapeutics targeting neurological disorders and cancer. This research briefing synthesizes the latest findings on the synthesis, biological activity, and pharmacological applications of this compound, providing a comprehensive overview for professionals in the field.
The compound's unique structural features, including its biphenyl and piperazine moieties, contribute to its ability to interact with a variety of biological targets. Recent research has focused on optimizing its pharmacokinetic properties and enhancing its selectivity for specific receptors. For instance, studies have demonstrated its efficacy as a modulator of serotonin and dopamine receptors, suggesting potential applications in the treatment of psychiatric disorders such as depression and schizophrenia.
In addition to its neurological applications, 1-Biphenyl-3-yl-piperazine has shown promise in oncology. Preclinical studies have revealed its ability to inhibit the proliferation of certain cancer cell lines by targeting key signaling pathways. These findings underscore the compound's potential as a lead candidate for the development of novel anticancer agents. Further research is needed to elucidate its mechanisms of action and to evaluate its safety and efficacy in clinical settings.
The synthesis of 1-Biphenyl-3-yl-piperazine has also been a focal point of recent investigations. Advances in synthetic methodologies have enabled the production of derivatives with improved bioavailability and reduced side effects. These developments are critical for the compound's transition from the laboratory to clinical trials. Researchers are now exploring the use of green chemistry principles to streamline the synthesis process, thereby reducing environmental impact and enhancing scalability.
In conclusion, 1-Biphenyl-3-yl-piperazine (CAS: 115761-61-0) represents a promising avenue for drug discovery and development. Its multifaceted biological activities and adaptable chemical structure make it a valuable tool for addressing unmet medical needs. Continued research efforts will be essential to fully realize its therapeutic potential and to translate these findings into clinical applications.
115761-61-0 (1-Biphenyl-3-yl-piperazine) Related Products
- 41186-03-2(1-(3-Methylphenyl)piperazine)
- 105907-65-1(1-(3,5-Dimethylphenyl)piperazine)
- 13078-13-2(1-(m-Tolyl)piperazine Dihydrochloride)
- 180698-19-5(1-Biphenyl-4-yl-piperazine)
- 163465-36-9(Piperazine, 1-(7-[1,1'-biphenyl]-4-yl-1-naphthalenyl)-4-methyl-)
- 1283736-97-9(3-methyl-5-(4-methylpiperazin-1-yl)aniline)
- 3477-33-6(Piperazine, 1,4-bis(3-methylphenyl)-)
- 649560-11-2(Piperazine, 1-(3-methylphenyl)-, hydrobromide (1:1))
- 151657-72-6(Piperazine,1-methyl-4-(3-methylphenyl)-)
- 7512-34-7(N,n'-bis[2-(diethylamino)ethyl]biphenyl-4,4'-diamine)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
